Redwood City, United States
Seer, founded in 2017, is at the forefront of the Biotechnology industry, with a mission encapsulated by its slogan: "Empowering scientists through unbiased, deep, rapid proteomics at scale." This innovative company is pioneering solutions to bridge the gap in proteomics technology that has historically limited the scope of biological research.
Seer is committed to providing the scientific community with advanced tools that facilitate unprecedented scientific discovery. By removing existing technological barriers, the company seeks to enable research that combines both large-scale studies and depth of coverage, a breakthrough mission that has previously been elusive in proteomics.
Having secured a substantial $175.00M IPO investment on 01 December 2020, Seer has demonstrated significant growth potential and investor confidence. The company’s focus on developing tools for accurate protein diversity analysis aligns with the expanding needs of health and disease research, marking it as a pivotal player aiming to revolutionize the field.
PrognomiQ Inc